New Ray Medicine International Holding Limited announced that based on a preliminary review and analysis of the latest available unaudited consolidated management accounts of the company, it is expected that the group will record a substantial increase in loss for the first six months ended 30 June 2017 as compared to a loss of approximately HKD 420,000 recorded by the Group for the six months ended 30 June 2016. Such substantial increase in loss was mainly attributable to the impairment losses of the Group's available-for-sale investments of approximately HKD 65.4 million for the first half of 2017 as a result of the volatile stock market in Hong Kong in the first half of 2017 as compared to the impairment losses of the Group's available-for- sale investments of approximately HKD 440,000 for the first half of 2016.